Treating 25% of all cancer cases in Saudi Arabia, with a 92% 5-year survival rate for childhood ALL
Yes. The King Fahad National Centre for Children's Cancer accepts 400+ new paediatric cases annually.
The programme carries COG, EBMT, NMDP, and CIBMTR accreditation, with a 92% 5-year survival rate for childhood ALL and 97% for renal tumours. Families receive accommodation guidance, airport coordination, and Arabic and English language support.
Cancer consultations, second opinions, and treatment coordination at KFSH&RC in Saudi Arabia are managed through the International Patient Care Centre:
The team is available 24/7 and can arrange online consultations, remote tumour board reviews, in-person appointments, and full oncology coordination with your assigned specialist.
Stay length depends on your procedure, your condition and how you recover. Your coordinator gives you a written itinerary with the expected stay for your case before you book flights.
The international patient team books accommodation near the hospital at no cost for the booking service, with options to suit your preference and budget, including space for a caregiver.
Yes. KFSH&RC has treated 200+ patients with CAR-T since 2020 and manufactures CAR-T cells locally, cutting preparation time by half. It is the only centre in the Arab world to do so. The therapy is used for treatment-resistant blood cancers including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, and multiple myeloma. Your coordinator confirms eligibility based on your diagnosis and treatment history before you proceed.
Three things set KFSH&RC apart:
Patients travelling from outside the GCC receive a Medical Referral Letter for their Saudi visa application, help with flights and accommodation, and Arabic and English coordination.